

# 土肉桂萃取液誘導飢餓素表現舒緩D-核糖引發之HepG2細胞死亡

黃致豪、李泰林

E-mail: 345449@mail.dyu.edu.tw

## 摘要

糖尿病患者中，因需長期服用降糖藥物、施打胰島素或糖代謝功能不彰等問題，常常伴隨有脂肪肝及藥物傷害等肝損傷問題存在。其中，據研究肉桂葉萃取液有改善糖尿病患者脂肪代謝及胰島素阻抗情形；本研究以核糖（D-ribose）誘發細胞內高氧化壓力，作為模擬糖尿病之環境，探討土肉桂萃取液對肝癌細胞株 - HepG2細胞之保護作用。本實驗採用三種本土不同化學類型土肉桂萃取液進行研究，分別為：桂皮醛-桂皮乙酸酯型（Cinnamaldehyde-cinnamylacetate type）（G2）、混合型（Mixed type）（P3）和台北市農會待測品種（TFA），實驗結果顯示皆可明顯減少細胞凋亡，並與已知用於糖尿病治療之用藥 - 氨基胍（Aminoguanidine, AG）效用相似（AG, P3, G2及TFA）分別各有：18.2%, 22.4%, 24.7%等恢復成效。土肉桂萃取液可促進飢餓素表現，而且受影響的以第一型變異產物（variable）為主，但第三型表現不受土肉桂之影響。另外，於D-ribose及土肉桂萃取液添加下，膜結合醯基轉移?4（MBOAT4）基因仍可表現，說明於HepG2細胞內，飢餓素仍有機會可受到醯化修飾。而Furin裂解蛋白為修飾飢餓素使其成為成熟的飢餓素之關鍵，在HepG2細胞中亦可被RT-PCR偵測到。因此，HepG2細胞亦可能將飢餓素原裂解成具功能性之飢餓素。最後，本實驗將飢餓素表現載體轉染到HepG2細胞，顯示具有保護細胞不受核糖傷害之效果。故未來可進一步探討土肉桂萃取液實際用於糖尿病患者中，以期在幫助糖代謝之外，亦可避免肝損傷、肝纖維化及肝硬化等後續肝功能傷害等問題產生。

關鍵詞：土肉桂、飢餓素、核糖

## 目錄

封面內頁 簽名頁 中文摘要 iii 英文摘要 v 誌謝 vi 目錄 ix 圖目錄 xiii 表目錄 xiv 1.前言 1 1.1 肉桂與土肉桂之簡介與應用 1 1.2 高糖與細胞壓力 2 1.2.1 氧化壓力（oxidative stress） 2 1.2.2 蛋白質糖化 3 1.2.3 肝醣生成與核糖（D-ribose）之氧化壓力 3 1.3 飢餓素（ghrelin）及其相關蛋白 5 1.3.1 飢餓素結構 5 1.3.2 飢餓素功能 6 1.3.3 飢餓素傳導路徑 6 1.3.4 飢餓素相關蛋白 7 1.4 肝臟疾病 9 1.4.1 肝損傷（liver injury） 9 1.4.2 肝纖維化（liver fibrosis） 10 1.4.3 肝硬化（liver cirrhosis） 11 1.4.4 肝癌（hepatic carcinoma） 12 1.5 研究動機 12 2. 材料方法 14 2.1 土肉桂成分之萃取 14 2.2 培養基之配備 15 2.2.1 HepG2細胞株之DMEM培養基 15 2.3 細胞培養 15 2.3.1 細胞培養之條件 15 2.3.2 細胞計數及繼代培養 16 2.4 HepG2細胞培養於高糖環境之條件 16 2.4.1 HepG2細胞培養於高糖環境與土肉桂萃取物誘導之處理 16 2.4.2 結晶紫染色（crystal violet stain, CV stain） 17 2.4.3 HepG2細胞RNA之萃取 17 2.4.4 反轉錄聚合?連鎖反應（reverse transcription polymerase chain reaction, RT-PCR） 18 2.4.5 洋菜膠體電泳（agarose gel electrophoresis） 19 2.5 人類第一及三型飢餓素變異體基因之選殖（gene cloning） 19 2.5.1 人類第一及三型飢餓素變異體基因全片段序列之聚合?連鎖反應 20 2.5.3 訊息勝？（signal peptide）序列之選殖 21 2.5.4 DNA接合作用調節之PCR（ligation-mediated PCR） 21 2.5.5 醋酸銨沉澱法 22 2.5.6 DNA接合作用（ligation） 22 2.5.7 勝任細胞（competent cell）製備及其質體選殖之轉形作用（transformation） 23 2.5.8 質體DNA小量製備（mini-preparation） 24 2.6 表現載體構築 24 2.6.1 表現載體之預處理 24 2.6.2 目標DNA之預處理 25 2.6.3 洋菜膠中洗滌出目標DNA片段（gel elution） 25 2.6.4 質體DNA大量製備（maxi-preparation） 26 2.7 HepG2細胞之轉染（transfection） 26 2.8 統計分析 27 2.8.1 半定量（semi-quantitation）PCR之統計分析 27 2.8.2 細胞計數之統計分析 28 3. 結果與討論 29 3.1 土肉桂萃取液對於HepG2細胞之影響 29 3.2 土肉桂萃取液對於HepG2細胞處於高糖環境之保護作用HepG2細胞於高糖環境之影響 29 3.3 各土肉桂萃取物於高糖環境下促表現不同變異類型之飢餓素 30 3.4 於高糖環境下膜結合醯基轉移?4（MBOAT4）表現量分析 30 3.5 飢餓素修飾蛋白 - Furin裂解蛋白之表現分析 31 3.6 第一型飢餓素基因變異體對HepG2於高糖環境之保護作用分析 31 3.7 第三型飢餓素基因變異體對HepG2於高糖環境之保護作用分析 32 4. 結論 33 參考文獻 50 附錄 58

## 參考文獻

- 王振瀾與尹華文。1992。土肉桂精油萃取、組成、季節性變化與葉部精油組成之天然變異。土肉桂專論 - 林業叢刊 (38) :47-61。台北，台灣。
- 行政院衛生署統計98年國人癌症十大統計數據：  
[http://www.doh.gov.tw/CHT2006/DM/DM2\\_2\\_p02.aspx?class\\_no=440&now\\_fod\\_list\\_no=11397&level\\_no=-1&doc\\_no=76512](http://www.doh.gov.tw/CHT2006/DM/DM2_2_p02.aspx?class_no=440&now_fod_list_no=11397&level_no=-1&doc_no=76512)
- 林讚標。1992。土肉桂專論 - 林業叢刊 (38)。台北，台灣。
- 胡家信。2008。肉桂萃取液對細胞生長的影響及其在化妝品上的應用。大葉大學。分子生物科技學系。彰化。台灣。
- 張上鎮。2002。土肉桂葉精油的抗細菌活性與應用。林業研究專訊9 (3) :23-28。
- 張上鎮。2003a。「傑出的生物化學家」 - 台灣鄉土林木。科學發展 (366) :6-11。
- 張上鎮。2003b。土肉桂葉子精油的生物活性與應用。台

灣林業28 ( 6 ) :31-35。 8.張上鎮，鄭森松，王升陽。2009。土肉桂飄香－葉子的神奇功效及應用。台灣林業35 ( 1 ) : 116-122。 9.許文馨。2010。土肉桂葉精油在STZ-糖尿病大鼠之降血糖作用。中山醫學大學。營養學研究所。台中。台灣。 10.Ariyasu H, Takaya K, Hosoda H, Iwakura H, Ebihara K, Mori K, Ogawa Y, Hosoda K, Akamizu T, Kojima M et al: Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. *Endocrinology* 2002, 143 ( 9 ) : 3341-3350. 11.Ariyasu H, Takaya K, Iwakura H, Hosoda H, Akamizu T, Arai Y, Kangawa K, Nakao K: Transgenic mice overexpressing des-acyl ghrelin show small phenotype. *Endocrinology* 2005, 146 ( 1 ) :355-364. 12.Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoi S, Fubini A, Malan D, Baj G, Granata R, Broglia F: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. *J Cell Biol* 2002, 159 ( 6 ) :1029-1037. 13.Bataller R, Brenner DA: Liver fibrosis. *J Clin Invest* 2005, 115 ( 2 ) :209-218. 14.Baynes JW: Role of oxidative stress in development of complications in diabetes. *Diabetes* 1991, 40 ( 4 ) :405-412. 15.Bierman EL, Baker EM, Plough IC, Hall WH: Metabolism of d-ribose in diabetes mellitus. *Diabetes* 1959, 8:455-458. 16.Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA: New aspects of hepatic fibrosis. *J Hepatol* 2000, 32 ( 1 Suppl ) :32-38. 17.Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 2005, 54 ( 6 ) :1615-1625. 18.Camina JP, Campos JF, Caminos JE, Dieguez C, Casanueva FF: Obestatin-mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. *J Cell Physiol* 2007, 211 ( 1 ) :1-9. 19.Carlini VP, Schiott HB, Debarioglio SR: Obestatin improves memory performance and causes anxiolytic effects in rats. *Biochemical and biophysical research communications* 2007, 352 ( 4 ) :907-912. 20.Chang ST, Chen PF, Chang SC: Antibacterial activity of leaf essential oils and their constituents from *Cinnamomum osmophloeum*. *J Ethnopharmacol* 2001, 77 ( 1 ) :123-127. 21.Chou JY, Mansfield BC: Gene therapy for type I glycogen storage diseases. *Curr Gene Ther* 2007, 7 ( 2 ) :79-88. 22.Chung H, Kim E, Lee DH, Seo S, Ju S, Lee D, Kim H, Park S: Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. *Endocrinology* 2007, 148 ( 1 ) :148-159. 23.D'Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. *Hepatology* 1995, 22 ( 1 ) :332-354. 24.Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci U S A* 2000, 97 ( 22 ) :12222-12226. 25.Fuller CJ, Chandalia M, Garg A, Grundy SM, Jialal I: RRR-alpha-tocopherol acetate supplementation at pharmacologic doses decreases low-density- lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. *Am J Clin Nutr* 1996, 63 ( 5 ) :753-759. 26.Ghosh K: Thrombohaemorrhagic balance in diabetes mellitus. *J Indian Med Assoc* 2002, 100 ( 7 ) :428, 430, 432-423. 27.Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, Destefanis S, Annunziata M, Martinetti M, Catapano F: Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. *Endocrinology* 2007, 148 ( 2 ) :512-529. 28.Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E: Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. *Diabetes* 2008, 57 ( 4 ) :967-979. 29.Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE: Ghrelin octanoylation mediated by an orphan lipid transferase. *Proc Natl Acad Sci U S A* 2008, 105 ( 17 ) :6320-6325. 30.Horie Y, Yamagishi Y, Kato S, Kajihara M, Kimura H, Ishii H: Low-dose ethanol attenuates gut ischemia/reperfusion-induced liver injury in rats via nitric oxide production. *J Gastroenterol Hepatol* 2003, 18 ( 2 ) :211-217. 31.Iseri SO, Sener G, Saglam B, Ercan F, Gedik N, Yegen BC: Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats. *Regul Pept* 2008, 146 ( 1-3 ) :73-79. 32.Kajimoto Y, Matsuoka T, Kaneto H, Watada H, Fujitani Y, Kishimoto M, Sakamoto K, Matsuhisa M, Kawamori R, Yamasaki Y: Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. *Diabetologia* 1999, 42 ( 12 ) :1417-1424. 33.Kamegai J, Tamura H, Shimizu T, Ishii S, Tatsuguchi A, Sugihara H, Oikawa S, Kineman RD: The role of pituitary ghrelin in growth hormone ( GH ) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. *Endocrinology* 2004, 145 ( 8 ) :3731-3738. 34.Kapica M, Zabielska M, Puzio I, Jankowska A, Kato I, Kuwahara A, Zabielski R: Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats - preliminary results. *J Physiol Pharmacol* 2007, 58 Suppl 3:123-130. 35.Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA: Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care* 2003, 26 ( 12 ) :3215-3218. 36.Kiefer MC, Tucker JE, Joh R, Landsberg KE, Saltman D, Barr PJ: Identification of a second human subtilisin-like protease gene in the fes/fps region of chromosome 15. *DNA Cell Biol* 1991, 10 ( 10 ) :757-769. 37.Kim SH, Hyun SH, Choung SY: Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. *J Ethnopharmacol* 2006, 104 ( 1-2 ) :119-123. 38.Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999, 402 ( 6762 ) :656-660. 39.Kui L, Weiwei Z, Ling L, Daikun H, Guoming Z, Linuo Z, Renming H: Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in adult rat cardiomyocytes through the PI3K-Akt signaling pathway. *Regul Pept* 2009, 155 ( 1-3 ) :62-69. 40.Lebrec D: Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. *Pharmacol Ther* 1994, 61 ( 1-2 ) :65-107. 41.Liang TJ, Heller T: Pathogenesis of hepatitis C-associated hepatocellular carcinoma. *Gastroenterology* 2004, 127 ( 5 Suppl 1 ) :S62-71. 42.McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA, London WT, Buetow KH: Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. *Cancer Res* 2003, 63 ( 15 ) :4594-4601. 43.Meszarosova M, Sirotnik AV, Grossmann R, Darlak K, Valenzuela F: The effect of obestatin on porcine ovarian granulosa cells. *Animal reproduction science* 2008, 108 ( 1-2 ) :196-207. 44.Moller P, Wallin H, Knudsen LE: Oxidative stress associated with exercise, psychological stress and life-style factors. *Chem*

Biol Interact 1996, 102 ( 1 ) :17-36. 45.Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C, Dominguez M, Conde L, Millan C: Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 2010, 51 ( 3 ) :974-985. 46.Muller TD, Tschop MH, Jarick I, Ehrlich S, Scherag S, Herpertz-Dahlmann B, Zipfel S, Herzog W, de Zwaan M, Burghardt R: Genetic variation of the ghrelin activator gene ghrelin O-acyltransferase ( GOAT ) is associated with anorexia nervosa. J Psychiatr Res 2011, 45 ( 5 ) :706-711. 47.Nelson DL. and Cox MM.: Lehninger principles of biochemistry. Fourth Edition edition. W. H. Freeman 2005 48.Niemela O, Parkkila S, Bradford B, Iimuro Y, Pasanen M, Thurman RG: Effect of Kupffer cell inactivation on ethanol-induced protein adducts in the liver. Free Radic Biol Med 2002, 33 ( 3 ) :350-355. 49.Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404 ( 6779 ) :787-790. 50.Park JM, Kakimoto T, Kuroki T, Shiraishi R, Fujise T, Iwakiri R, Fujimoto K: Suppression of intestinal mucosal apoptosis by ghrelin in fasting rats. Exp Biol Med ( Maywood ) 2008, 233 ( 1 ) :48-56. 51.Pazos Y, Alvarez CJ, Camina JP, Casanueva FF: Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin. Growth Factors 2007, 25 ( 6 ) :373-381. 52.Rehermann B: Immune responses in hepatitis B virus infection. Semin Liver Dis 2003, 23 ( 1 ) :21-38. 53.Ren AJ, Guo ZF, Wang YK, Wang LG, Wang WZ, Lin L, Zheng X, Yuan WJ: Inhibitory effect of obestatin on glucose-induced insulin secretion in rats. Biochemical and biophysical research communications 2008, 369 ( 3 ) :969-972. 54.Roebroek AJ, Schalken JA, Leunissen JA, Onnekink C, Bloemers HP, Van de Ven WJ: Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. EMBO J 1986, 5 ( 9 ) :2197-2202. 55.Romero A, Kirchner H, Heppner K, Pfluger PT, Tschop MH, Nogueiras R: GOAT: the master switch for the ghrelin system? Eur J Endocrinol 2010, 163 ( 1 ) :1-8. 56.Ryman BE: The glycogen storage diseases. J Clin Pathol Suppl ( R Coll Pathol ) 1974, 8:106-121. 57.Samson WK, White MM, Price C, Ferguson AV: Obestatin acts in brain to inhibit thirst. American journal of physiology Regulatory, integrative and comparative physiology 2007, 292 ( 1 ) :R637-643. 58.Schafer T, Scheuer C, Roemer K, Menger MD, Vollmar B: Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J 2003, 17 ( 6 ) :660-667. 59.Schuppan D: Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990, 10 ( 1 ) :1-10. 60.Segal S, Foley J: The metabolism of D-ribose in man. The Journal of clinical investigation 1958, 37 ( 5 ) :719-735. 61.Stengel A, Goebel M, Wang L, Tache Y, Sachs G, Lambrecht NW: Differential distribution of ghrelin-O-acyltransferase ( GOAT ) immunoreactive cells in the mouse and rat gastric oxytic mucosa. Biochem Biophys Res Commun 2010, 392 ( 1 ) :67-71. 62.Stickel F, Brinkhaus B, Krahmer N, Seitz HK, Hahn EG, Schuppan D: Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology 2002, 49 ( 46 ) :1102-1108. 63.Szentirmai E, Krueger JM: Obestatin alters sleep in rats. Neuroscience letters 2006, 404 ( 1-2 ) :222-226. 64.Takahashi T, Ida T, Sato T, Nakashima Y, Nakamura Y, Tsuji A, Kojima M: Production of n-octanoyl-modified ghrelin in cultured cells requires prohormone processing protease and ghrelin O-acyltransferase, as well as n-octanoic acid. J Biochem 2009, 146 ( 5 ) :675-682. 65.Thomson WH, Maclaurin JC, Prineas JW: Skeletal muscle glycogenosis: an investigation of two dissimilar cases. J Neurol Neurosurg Psychiatry 1963, 26:60-68. 66.Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S: Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001, 281 ( 5 ) :1220-1225. 67.Vinik A, Flemmer M: Diabetes and macrovascular disease. J Diabetes Complications 2002, 16 ( 3 ) :235-245. 68.Wise RJ, Barr PJ, Wong PA, Kiefer MC, Brake AJ, Kaufman RJ: Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. Proc Natl Acad Sci USA 1990, 87 ( 23 ) :9378-9382. 69.Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310 ( 5750 ) :996-999. 70.Zhang Y, Ying B, Shi L, Fan H, Yang D, Xu D, Wei Y, Hu X, Zhang X, Wang T: Ghrelin inhibit cell apoptosis in pancreatic beta cell line HIT-T15 via mitogen-activated protein kinase/phosphoinositide 3-kinase pathways. Toxicology 2007, 237 ( 1-3 ) :194-202.